- China
- /
- Healthtech
- /
- SZSE:300451
B-SOFTLtd Third Quarter 2024 Earnings: EPS: CN¥0.01 (vs CN¥0.031 in 3Q 2023)
B-SOFTLtd (SZSE:300451) Third Quarter 2024 Results
Key Financial Results
- Revenue: CN¥441.9m (down 2.4% from 3Q 2023).
- Net income: CN¥25.4m (down 62% from 3Q 2023).
- Profit margin: 5.7% (down from 15% in 3Q 2023).
- EPS: CN¥0.01 (down from CN¥0.031 in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
B-SOFTLtd Earnings Insights
Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 16% growth forecast for the Healthcare Services industry in Asia.
Performance of the market in China.
The company's shares are up 5.3% from a week ago.
Risk Analysis
It is worth noting though that we have found 1 warning sign for B-SOFTLtd that you need to take into consideration.
Valuation is complex, but we're here to simplify it.
Discover if B-SOFTLtd might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About SZSE:300451
Flawless balance sheet with reasonable growth potential.